APPLIED CLINICAL TRIALS Issue Alert Having trouble viewing this email? Click here
Web Version | View Digital Edition | Subscribe
In our January/February issue:

SURVEY SPOTLIGHT

Patient Engagement: Are We There Yet?
Findings from a new ACT and SCORR Marketing survey reveal a gap in the shift to true patient engagement in clinical trials, but overall measures do signal growth in patient-centric activities.

PEER-REVIEWED ARTICLES

Social Media’s Clinical Impact
Nimita Limaye, PhD, Awani Saraogi
With social media introducing a pragmatic component to clinical trials—and supporting the world of evidence-based medicine—this report examines the growing utility of social media in adverse event reporting and advancing patient-centric initiatives in drug development.
The MS Trial Imperative: Reducing Risk
Marie Trad, MD, Cathy Vanbelle, Benjamin Moody, PhD, Amy Del Medico, Olija Tanjga, MD, Sam Khinda, Lynne Hughes, PhD
Despite the market authorization of 16 therapies for multiple sclerosis (MS), there is still no cure for this debilitating disease. Authors explore the key challenges in designing and executing multi-regional clinical trials for MS—and propose mitigation strategies that may help reduce the burden from these associated risks.
NEWS

Washington Report: Jill Wechsler on FDA’s goal to maintain momentum in speeding breakthrough drugs to patients.

EU Report: Peter O’Donnell looks at efforts in Europe to improve R&D communication and trust with investors and the public.

Data Management: An expert view on how sponsors can formalize the use of real-world data and generation of real-world evidence to drive critical insights.

CISCRP CORNER

Public Clinical Research Literacy: New Insights
CISCRP Research Services: Annick Anderson, Jasmine Benger, Nova Getz
The first series of results from the Center for Information and Study on Clinical Research Participation’s (CISCRP) landmark 2017 Perceptions & Insights Study.
CLOSING THOUGHT

The Frontier for Dermatology Biologics
Darcee Strube
To vie for success in the market for dermatologic therapies, companies developing biologics must navigate a series of significant challenges, including patient compliance and safety.

Download the
issue:
image
 
BLOGS
More Streamlined Clinical Research Arises from Collaborative Effort
Are Safety Signals Overlooked in Clinical Trials?
Expected Changes to the Vendor Landscape in 2018
WEBCAST
Immuno-Gene Therapy in Hematological Cancers: How Science Drives Study Strategy
Find out the current state of technology in gene therapeutics, including trends in immuno-oncology and gene therapy for hematological malignancies.

If you would like to submit an article to Applied Clinical Trials, contact Lisa Henderson, Editorial Director - lisa.henderson@ubm.com

Applied Clinical Trials is free to qualified subscribers. To subscribe, click here.

Click here to contact the Applied Clinical Trials sales team.

Twitter LinkedIn